Primus Pharmaceuticals   Report issue

For profit Phase 1 Phase 3
Founded: Scottsdale AZ United States (2001)
Status: No NME R&D (2001)

Organization Overview

First Clinical Trial
2005
NCT00626769
First Marketed Drug
2015
metaxalone (skelaxin)
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Primus Pharmaceuticals | Primus Pharmaceuticals,Inc | Primus Pharmaceuticals, Inc | PRIMUS PHARMS

Active Ingredients

Marketed Drugs (3)

betamethasone (celestone) (2016)

clobetasol (dermovate) (2017)

metaxalone (skelaxin) (2015)

Drugs in Phase 3 Trials (1)

genistein (1 trial)

Drugs in Phase 1 Trials (2)

catechin (5 trials)

tj-14 (5 trials)

Drugs in Other Trials (6)

cellulose (1 trial)

diosmin (2 trials)

naproxen (naprosyn) (4 trials)

povidone (1 trial)

silicon dioxide (1 trial)

stearic acid (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Osteoarthritis (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 9
  • # of Trial APIs: 9